Friday 19 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

A Huge Market Awaits Fertility Pioneer Concepta

By Malcolm Stacey | Friday 2 September 2016

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Hello Share Squaddies. May I bring to your attention another medical outfit which has a very encouraging market to have a go at. The firm is Concepta (CPT) and it has produced something it calls MyLotus. These are clever devices which test fertility in women, as well as being an indicator of pregnancy.

It’s something to do with hormones and urine samples, but of course, the details are beyond me. The kits are not likely to be very cheap and could sell for about £250 on a commercial basis. However we know, don’t we, that people will usually  stump up where their health and welfare is concerned.

There is no permission to sell MyLotus kits in the UK, or indeed Europe, but this is expected in 2017. And in China the kits have the green light and will go on sale there this year. A selling network is already in place for that.

Also, Concepta has other irons in the fire of medical pioneering. It is working on kits to diagnose stress. Though this is linked to the effects of stress on fertility, it may have a wider customer base, including men. 

Stress is always hard to prove and devices to detect it would be useful. One imagines, perhaps, it could be employed to persuade cynical bosses that you really can’t work at the moment.

The City seems to quite like this company: the shares rose by about 50% last month alone. It’s an AIM member, based in York, and the market cap is about £20m.

The Chairman Adam Reynolds says it aims to become a global leader in over-the-counter fertility products. And he reckons the firm could come in early on a connected global healthcare market worth $60 billion dollars by 2020.

I know that sort of hope is easy to express, but you never know.

As we always say in the Punter’s Return.

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on CPT


Comments are turned off for this article.

Site by Everywhen